Pfizer Inc. $PFE Shares Purchased by Mitsubishi UFJ Asset Management Co. Ltd.

Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 4.2% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 11,396,271 shares of the biopharmaceutical company’s stock after purchasing an additional 464,449 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Pfizer were worth $290,377,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Grey Fox Wealth Advisors LLC purchased a new stake in Pfizer during the 3rd quarter worth $29,000. Howard Hughes Medical Institute acquired a new position in shares of Pfizer during the second quarter worth about $30,000. True Wealth Design LLC boosted its position in shares of Pfizer by 302.5% in the third quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 974 shares during the period. Darwin Wealth Management LLC purchased a new stake in shares of Pfizer in the second quarter worth about $32,000. Finally, Evelyn Partners Asset Management Ltd acquired a new stake in shares of Pfizer in the second quarter valued at about $33,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on PFE. BMO Capital Markets reissued an “outperform” rating on shares of Pfizer in a research report on Wednesday, December 10th. Cantor Fitzgerald reissued a “neutral” rating and set a $27.00 target price on shares of Pfizer in a research report on Wednesday, February 4th. Sanford C. Bernstein restated a “market perform” rating and issued a $30.00 target price on shares of Pfizer in a research note on Friday, October 31st. UBS Group assumed coverage on shares of Pfizer in a report on Tuesday, January 6th. They set a “neutral” rating and a $25.00 price target for the company. Finally, Daiwa Securities Group lowered shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price objective on the stock. in a report on Thursday, February 12th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have issued a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $27.70.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: FDA gives full approval to Pfizer’s BRAFTOVI combination for first‑line metastatic colorectal cancer — a clear commercial positive for oncology revenue and uptake. Read More.
• Positive Sentiment: Pfizer secures China commercialization partner (Sciwind) for a next‑generation weight‑loss GLP‑1 candidate, expanding market access in a high‑growth obesity/diabetes segment and unlocking up to ~$495M in deal value. Read More.
• Positive Sentiment: Dividend narratives strengthen investor interest — coverage pieces highlight Pfizer’s high yield and management’s commitment to the payout, supporting income‑oriented demand. Read More.
• Neutral Sentiment: Pfizer updated clinical activity in China (pneumococcal vaccine Phase 1) — constructive for long‑term vaccine opportunity but near‑term commercial impact is unclear. Read More.
• Neutral Sentiment: Industry pieces and comparisons (Novo Nordisk, J&J, large‑cap pharma commentary) are placing Pfizer within a broader sector narrative about defensiveness and AI‑driven R&D — useful context but not company‑specific catalysts. Read More.
• Negative Sentiment: RBC Capital initiated coverage with an Underperform/“$25” target and warned of an expected $15B–$20B structural revenue decline through 2030 — a significant bearish forecast that pressures valuation expectations. Read More.
• Negative Sentiment: Zacks moved Pfizer from “strong sell” to “hold,” improving its tone but reflecting continued analyst caution; RBC/other outlets are still negative which keeps analyst sentiment mixed. Read More.
• Negative Sentiment: Pfizer terminated an early‑stage ulcerative colitis study (Phase 1b), representing a pipeline setback and incremental downside risk to future growth prospects. Read More.

Pfizer Stock Performance

Shares of PFE opened at $27.11 on Thursday. The stock has a market capitalization of $154.11 billion, a PE ratio of 19.93 and a beta of 0.47. The business’s fifty day moving average price is $26.04 and its 200 day moving average price is $25.37. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $27.94.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.25%. The company had revenue of $17.56 billion for the quarter, compared to analysts’ expectations of $16.93 billion. During the same period in the prior year, the company earned $0.63 earnings per share. The firm’s revenue was down 1.2% compared to the same quarter last year. Equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.3%. The ex-dividend date is Friday, January 23rd. Pfizer’s payout ratio is presently 126.47%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.